Special Issue

Metal Nanoplatforms as Controlled Release and Targeted Drug Carriers and Hyperthermia Agents

Message from the Guest Editor

Cancer is one of the leading causes of death globally. Unfortunately, conventional treatment methods such as bulk chemotherapy and radiation therapy are associated with toxic side effects for patients. Therefore, increasing the therapeutic efficacy of anticancer agents, while decreasing their toxicity, has become an important research area. The two approaches used include the controlled release drug delivery and targeted drug delivery. A recently developed paradigm involves employing hyperthermia/heat delivery to shrink tumors. This is especially relevant as an adjuvant therapy for killing residual cancer cells to prevent tumor recurrence following tumor resection surgery or chemotherapy. In this context, metal nanoparticles have been synthesized and/or modified with various functional groups to allow their use as (a) nanocarriers for controlled release and targeted drug delivery or (b) thermoseeds for hyperthermia. This Special Issue aims to highlight current research on the development and in vitro/in vivo evaluation of metal nanocarriers for controlled drug release, targeted drug delivery, and/or hyperthermia delivery for cancer therapy.

Guest Editor

Dr. Ali A. Salifu

Department of Engineering, Boston College, Chestnut Hill, MA 02467, USA

Deadline for manuscript submissions

closed (31 October 2023)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/151551

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

